Lucy Therapeutics Appoints Kim Drapkin as Board Chair
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
Stifel Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
Strong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193
Express News | Acumen Pharmaceuticals Inc - Lonza to Provide DP Manufacturing Services From Visp Site
Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease
Express News | Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Express News | Acumen Pharmaceuticals Inc : UBS Cuts Target Price to $6 From $14
UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $6
Acument Pharmaceuticals Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After the Company Reported Worse-than-expected Q2 EPS Results Yesterday.
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 38.9%
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Andrew Fein maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 4
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer's Treatment Advances and Strong Financials
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals Analyst Ratings
Q2 2024 Acumen Pharmaceuticals Inc Earnings Call